# A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With Colorectal Cancer

> **NCT02613221** · PHASE1,PHASE2 · COMPLETED · sponsor: **Takeda** · enrollment: 56 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Panitumumab + TAS-102

## Key facts

- **NCT ID:** NCT02613221
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-07
- **Primary completion:** 2017-10-06
- **Final completion:** 2018-03-30
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2019-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02613221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02613221, "A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With Colorectal Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02613221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*